Literature DB >> 28768860

Zinc Finger-Containing Cellular Transcription Corepressor ZBTB25 Promotes Influenza Virus RNA Transcription and Is a Target for Zinc Ejector Drugs.

Shu-Chuan Chen1, King-Song Jeng1,2, Michael M C Lai3,4,5.   

Abstract

Influenza A virus (IAV) replication relies on an intricate interaction between virus and host cells. How the cellular proteins are usurped for IAV replication remains largely obscure. The aim of this study was to search for novel and potential cellular factors that participate in IAV replication. ZBTB25, a transcription repressor of a variety of cellular genes, was identified by an RNA interference (RNAi) genomic library screen. Depletion of ZBTB25 significantly reduced IAV production. Conversely, overexpression of ZBTB25 enhanced it. ZBTB25 interacted with the viral RNA-dependent RNA polymerase (RdRp) protein and modulated its transcription activity. In addition, ZBTB25 also functioned as a viral RNA (vRNA)-binding protein, binding preferentially to the U-rich sequence within the 5' untranslated region (UTR) of vRNA. Both protein-protein and protein-RNA interactions involving ZBTB25 facilitated viral RNA transcription and replication. In addition, ZBTB25 suppressed interferon production, further enhancing viral replication. ZBTB25-associated functions required an intact zinc finger domain and posttranslational SUMO-1 modification of ZBTB25. Furthermore, treatment with disulfiram (a zinc ejector) of ZBTB25-overexpressing cells showed significantly reduced IAV production as a result of reduced RNA synthesis. Our findings indicate that IAV usurps ZBTB25 for IAV RNA synthesis and serves as a novel and potential therapeutic antiviral target.IMPORTANCE IAV-induced seasonal influenza causes severe illness and death in high-risk populations. However, IAV has developed resistance to current antiviral drugs due to its high mutation rate. Therefore, development of drugs targeting cellular factors required for IAV replication is an attractive alternative for IAV therapy. Here, we discovered a cellular protein, ZBTB25, that enhances viral RdRp activity by binding to both viral RdRp and viral RNA to stimulate viral RNA synthesis. A unique feature of ZBTB25 in the regulation of viral replication is its dual transcription functions, namely, promoting viral RNA transcription through binding to the U-rich region of vRNA and suppressing cellular interferon production. ZBTB25 contains a zinc finger domain that is required for RNA-inhibitory activity by chelating zinc ions. Disulfiram treatment disrupts the zinc finger functions, effectively repressing IAV replication. Based on our findings, we demonstrate that ZBTB25 regulates IAV RNA transcription and replication and serves as a promising antiviral target for IAV treatment.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  IAV replication; ZBTB25; influenza A virus

Mesh:

Substances:

Year:  2017        PMID: 28768860      PMCID: PMC5625503          DOI: 10.1128/JVI.00842-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

Review 1.  POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function.

Authors:  Sung-Uk Lee; Takahiro Maeda
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

2.  A family of human zinc finger proteins that bind methylated DNA and repress transcription.

Authors:  Guillaume J P Filion; Svetlana Zhenilo; Sergey Salozhin; Daisuke Yamada; Egor Prokhortchouk; Pierre-Antoine Defossez
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

3.  A host susceptibility gene, DR1, facilitates influenza A virus replication by suppressing host innate immunity and enhancing viral RNA replication.

Authors:  Shih-Feng Hsu; Wen-Chi Su; King-Song Jeng; Michael M C Lai
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

Review 4.  Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

Authors:  Thomas A Rasmussen; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

5.  Inhibition of filovirus replication by the zinc finger antiviral protein.

Authors:  Stefanie Müller; Peggy Möller; Matthew J Bick; Stephanie Wurr; Stephan Becker; Stephan Günther; Beate M Kümmerer
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

Review 6.  The BTB-ZF transcription factors.

Authors:  Owen M Siggs; Bruce Beutler
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

7.  The BTB-ZF family of transcription factors: key regulators of lineage commitment and effector function development in the immune system.

Authors:  Aimee M Beaulieu; Derek B Sant'Angelo
Journal:  J Immunol       Date:  2011-09-15       Impact factor: 5.422

8.  Changes in cellular mRNA stability, splicing, and polyadenylation through HuR protein sequestration by a cytoplasmic RNA virus.

Authors:  Michael D Barnhart; Stephanie L Moon; Alexander W Emch; Carol J Wilusz; Jeffrey Wilusz
Journal:  Cell Rep       Date:  2013-11-07       Impact factor: 9.423

9.  Xenopus transcription factor A requires zinc for binding to the 5 S RNA gene.

Authors:  J S Hanas; D J Hazuda; D F Bogenhagen; F Y Wu; C W Wu
Journal:  J Biol Chem       Date:  1983-12-10       Impact factor: 5.157

10.  Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.

Authors:  Xueqing Lun; J Connor Wells; Natalie Grinshtein; Jennifer C King; Xiaoguang Hao; Ngoc-Ha Dang; Xiuling Wang; Ahmed Aman; David Uehling; Alessandro Datti; Jeffrey L Wrana; Jacob C Easaw; Artee Luchman; Samuel Weiss; J Gregory Cairncross; David R Kaplan; Stephen M Robbins; Donna L Senger
Journal:  Clin Cancer Res       Date:  2016-03-22       Impact factor: 12.531

View more
  1 in total

1.  Zinc Chelation Specifically Inhibits Early Stages of Dengue Virus Replication by Activation of NF-κB and Induction of Antiviral Response in Epithelial Cells.

Authors:  Meenakshi Kar; Naseem Ahmed Khan; Aleksha Panwar; Sachendra S Bais; Soumen Basak; Renu Goel; Shailaja Sopory; Guruprasad R Medigeshi
Journal:  Front Immunol       Date:  2019-10-01       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.